Your Best Stock
Stocks Biotechnology VRTX

Vertex Pharmaceuticals VRTX

US equityMarket cap rank #116BiotechnologyGene Editing
$520.94
+$4.60 (+0.89%)
Market open · Sep 24, 1:10 pm ET
After hours $517.00 +0.13%
Open$515.56
Prev close$516.34
Day range$515.30 – $528.89
Volume332.9K
Market cap$132.04B
P/E (TTM)30.3
Dividend yield

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$3.33B+12.5% YoY
Operating profit$1.27B+9.9% YoY
Net profit$1.10B+6.5% YoY
Diluted EPS$4.31+8.0% YoY
Free cash flow$1.01B+9.3% YoY
Operating cash flow$1.13B

Revenue, last 8 quarters

$2.8BSep '24$2.9BDec '24$2.8BMar '25$3.0BJun '25$3.1BSep '25$3.2BDec '25$3.0BMar '26$3.3BJun '26

Net profit, last 8 quarters

$1.0BSep '24$913.0MDec '24$646.3MMar '25$1.0BJun '25$1.1BSep '25$1.2BDec '25$1.0BMar '26$1.1BJun '26

Diluted EPS by quarter

4.01Sep '243.50Dec '242.49Mar '253.99Jun '254.20Sep '254.65Dec '254.02Mar '264.31Jun '26

Free cash flow by quarter

$1.3BSep '24$492.0MDec '24$778.2MMar '25$927.4MJun '25$1.1BSep '25$348.6MDec '25$1.3BMar '26$1.0BJun '26

Annual revenue

$6.2BFY20$7.6BFY21$8.9BFY22$9.9BFY23$11.0BFY24$12.0BFY25

Profitability & balance sheet

Gross margin86.0%
Operating margin37.9%
Net margin35.0%
Return on equity23.5%
Return on assets17.1%
Return on invested capital19.5%
Current ratio3.19
Liabilities / assets26.2%
Cash & investments$7.85B
Total debt$1.98B
Net cash (debt)$5.87B
Free cash flow / sales30.2%

Where the revenue comes from

Quarter 2026/Q2

By business line

  • TRIKAFTA/KAFTRIO$2.50B 74.9%
  • ALYFTREK$573.60M 17.2%
  • Other cystic fibrosis (CF) products$137.10M 4.1%
  • CASGEVY$76.40M 2.3%
  • JOURNAVX$49.60M 1.5%

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Revenue as Reported $3.33B $2.99B $12.00B $3.19B $3.08B
Total Operating Revenue $3.33B $2.99B $12.00B $3.19B $3.08B
Cost of Revenue $489.20M $392.80M $1.65B $466.00M $414.80M
Gross Profit $2.84B $2.59B $10.35B $2.72B $2.66B
Operating Expense $1.58B $1.46B $5.80B $1.59B $1.42B
Selling and Admin Expenses $582.20M $493.70M $1.75B $487.00M $445.10M
Research & Development $993.80M $961.60M $4.04B $1.11B $977.70M
Operating Profit $1.27B $1.14B $4.55B $1.13B $1.24B
Net Non-Operating Interest Income (Expense) $120.60M $114.80M $477.60M $118.60M $122.40M
Non-Operating Interest Income $120.60M $114.80M $490.90M $121.90M $125.70M
Other Income (Expense) $2.50M -$700,000.00 -$388.80M $82.10M -$62.40M
Special Income (Charges) -$21.80M -$700,000.00 -$381.10M $75.60M -$52.60M
-Less:Restructuring and Mergern & Acquisition $400,000.00 $200,000.00 $2.10M $900,000.00 -$1.90M
-Less:Impairment of Capital Assets $0.00 $0.00 $379.00M $0.00 $0.00
-Less:Other Special Charges $21.40M $500,000.00 $54.50M
Other Non-Operating Income (Expenses) $24.30M -$7.70M $6.50M -$9.80M
Pretax Profit $1.39B $1.25B $4.64B $1.33B $1.30B
Tax $292.00M $221.50M $690.00M $139.90M $215.90M
Net Profit $1.10B $1.03B $3.95B $1.19B $1.08B
Profit from Continuing Operations $1.10B $1.03B $3.95B $1.19B $1.08B
Net Income to Parent Company $1.10B $1.03B $3.95B $1.19B $1.08B
Net Income to Common Stockholders $1.10B $1.03B $3.95B $1.19B $1.08B
Basic EPS $4.34 $4.06 $15.46 $4.69 $4.24
Diluted EPS $4.31 $4.02 $15.32 $4.65 $4.20
Non-Operating Interest Expense $13.30M $3.30M $3.30M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Total Assets $27.42B $26.48B $25.64B $25.64B $24.86B
Total Current Assets $12.54B $11.73B $11.20B $11.20B $10.57B
Cash and Cash Equivalents & Short-Term Investments $7.85B $7.25B $6.61B $6.61B $6.29B
-Cash and Cash Equivalents $6.14B $5.49B $5.08B $5.08B $4.94B
-Short Term Investments $1.71B $1.75B $1.52B $1.52B $1.35B
Receivables $2.13B $2.00B $2.05B $2.05B $1.95B
-Accounts Receivable $2.13B $2.00B $2.05B $2.05B $1.95B
Inventory $1.77B $1.77B $1.69B $1.69B $1.63B
Other Current Assets $791.90M $720.80M $110.90M $110.90M $709.40M
Total Non-Current Assets $14.88B $14.75B $14.44B $14.44B $14.29B
Net PPE $3.33B $3.29B $3.08B $3.08B $3.02B
-Gross PPE $3.33B $3.29B $4.29B $4.29B $3.02B
Investments and Advances $5.79B $5.75B $5.71B $5.71B $5.72B
-Available for Sale Securities $5.79B $5.75B $5.71B $5.71B $5.72B
Goodwill and Other Intangible Assets $1.50B $1.51B $1.51B $1.51B $1.52B
-Goodwill $1.09B $1.09B $1.09B $1.09B $1.09B
-Other Intangible Assets $412.80M $418.50M $424.20M $424.20M $429.80M
Non-Current Deferred Assets $3.01B $2.95B $2.90B $2.90B $2.94B
Other Non-Current Assets $1.25B $1.26B $1.24B $1.24B $1.10B
Total Liabilities $7.18B $7.12B $6.98B $6.98B $7.54B
Total Current Liabilities $3.94B $3.88B $3.86B $3.86B $4.48B
Payables $429.50M $489.30M $893.00M $893.00M $420.30M
-Accounts Payable $429.50M $489.30M $461.70M $461.70M $420.30M
Current Accrued Expenses $3.18B $2.98B $2.59B $2.59B $3.61B
Other Current Liabilities $329.40M $407.10M $127.70M $127.70M $441.50M
Total Non-Current Liabilities $3.24B $3.24B $3.12B $3.12B $3.07B
Long Term Debt and Capital Lease Obligation $1.98B $1.99B $1.95B $1.95B $1.83B
-Long Term Capital Lease Obligation $1.98B $1.99B $1.95B $1.95B $1.83B
Other Non-Current Liabilities $1.26B $1.26B $267.40M $267.40M $1.23B
Total Equity $20.25B $19.36B $18.67B $18.67B $17.32B
Stockholders' Equity $20.25B $19.36B $18.67B $18.67B $17.32B
Capital Stock $2.50M $2.50M $2.50M $2.50M $2.50M
-Common Stock $2.50M $2.50M $2.50M $2.50M $2.50M
-Preferred Stock $0.00 $0.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $4.51B $4.74B $5.12B $5.12B $5.01B
Retained Earnings $15.69B $14.59B $13.56B $13.56B $12.37B
Gains/Losses Not Affecting Retained Earnings $48.50M $24.80M -$15.90M -$15.90M -$64.50M
Prepaid Assets $736.20M $736.20M
-Accumulated Depreciation -$1.20B -$1.20B
-Total Tax Payable $103.10M $103.10M
-Other Payable $328.20M $328.20M
Short-Term Debt and Capital Lease Obligation $77.30M $77.30M
-Current Capital Lease Obligation $77.30M $77.30M
Current Deferred Liabilities $171.80M $171.80M
Long Term Accounts Payable and Other Payables $895.40M $895.40M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4 2025 Q3
Operating Cash Flow $1.13B $1.43B $3.63B $498.00M $1.24B
Net cash flow from continuing operations $1.13B $1.43B $3.63B $498.00M $1.24B
Net Income from Continuing Operations $1.10B $1.03B $3.95B $1.19B $1.08B
Depreciation & Depletion & Amortization $56.50M $55.90M $209.80M $55.70M $54.00M
Deferred Tax -$69.70M -$65.30M -$510.80M $30.50M -$235.90M
Other Non-Cash Items -$16.40M -$5.00M $113.40M $23.10M -$16.30M
Change in Working Capital -$115.00M $244.70M -$1.20B -$947.80M $149.60M
-Change in Receivables -$140.20M $39.80M -$347.30M -$99.40M -$59.90M
-Change in Inventory -$27.70M -$97.70M -$524.20M -$77.40M -$131.10M
-Change in Prepaid Assets -$51.40M $173.40M -$396.00M -$250.60M -$40.90M
-Change in Payables and Accrued Expense $155.80M $106.10M -$80.10M -$626.20M $297.60M
-Change in Other Current Liabilities -$51.50M $23.10M $148.50M $105.80M $83.90M
Net cash flow from investing -$45.80M -$431.90M -$945.40M -$288.10M -$117.00M
Net Cash Flow from Continuing Investing Activities -$45.80M -$431.90M -$945.40M -$288.10M -$117.00M
Net PPE Purchase and Sale -$112.20M -$133.40M -$437.60M -$149.40M -$101.80M
Net Investment Purchase and Sale $68.10M -$298.50M -$483.10M -$122.80M -$16.00M
Financing Cash Flow -$426.70M -$538.80M -$2.26B -$77.20M -$1.15B
Net Cash Flow from Continuing Financing Activities -$426.70M -$538.80M -$2.26B -$77.20M -$1.15B
Net Common Stock Issuance -$473.80M -$565.40M -$2.39B -$130.90M -$1.16B
Proceeds from Stock Option Exercised $47.70M $27.00M $127.70M $54.00M $7.90M
Net Other Financing Charges -$600,000.00 -$400,000.00 $3.70M $1.10M $3.70M
Ending Cash Balance $6.15B $5.50B $5.09B $5.09B $4.95B
Net Change in Cash $652.90M $457.40M $424.70M $132.70M -$30.10M
Beginning Cash Balance $5.50B $5.09B $4.57B $4.95B $4.98B
Effect of Exchange Rate Changes -$3.70M -$40.30M $90.90M $7.30M -$4.10M
Free Cash Flow $1.01B $1.29B $3.19B $348.60M $1.14B
Net Intangibles Purchase and Sale $0.00 $0.00 $0.00
Net Other Investing Changes -$24.70M -$15.90M $800,000.00
Net Issuance Payments Of Debt -$5.40M -$1.40M -$1.40M
Gain/Loss from Continuing Operations $2.60M
Scroll to Top